A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Brief summary

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

Observational study

998 patients
Protocol ID:
Observational model:
Time perspective:


Eligibility criteria

Participant attributes:
Male and Female


18 Years and older.

Inclusion Criteria:

- Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary
myelofibrosis (SMF)].

- Must have initiated their first treatment on or after the first date when ruxolitinib
was approved in their country of residence and no later than 31 December 2021.

Exclusion Criteria:

- Having received MF treatment in a clinical trial setting.

All the cities where the clinical studies are located

Vancouver - V6Z 1Y6
Halifax - B3H 1V7
Hamilton - L8V 1C3
Toronto - M5G 2M9
Levis - G6V 3Z1
Montreal - H1T 2M4
Montreal - H3T 1E2

British Columbia

Nova Scotia

More information about this study